COVID-19 (Coronavirus) Information
Your health and safety are our top priorities. Learn more about our COVID-19 evaluation and testing and our commitment to providing great care while maintaining the safest environment possible.
Juvenile rheumatoid arthritis (JRA); Juvenile chronic polyarthritis; Still disease; Juvenile spondyloarthritis
Juvenile idiopathic arthritis (JIA) is a term used to describe a group of disorders in children that includes arthritis. They are long-term (chronic) diseases that cause joint pain and swelling. The names describing this group of conditions has changed over the past several decades as more is learned about the condition.
The cause of JIA is not known. It is thought to be an autoimmune illness. This means the body attacks and destroys healthy body tissue by mistake.
JIA most often develops before age 16. Symptoms may start as early as 6 months old.
The International League of Associations for Rheumatology (ILAR) has proposed the following way of grouping this type of childhood arthritis:
Symptoms of JIA may include:
JIA can also cause eye problems called uveitis, iridocyclitis, or iritis. There may be no symptoms. When eye symptoms occur, they can include:
The physical exam may show swollen, warm, and tender joints that hurt to move. The child may have a rash. Other signs include:
Blood tests may include:
Any or all of these blood tests may be normal in children with JIA.
The health care provider may place a small needle into a swollen joint to remove fluid. This can help to find the cause of the arthritis. It can also help relieve pain. The provider may inject steroids into the joint to help reduce swelling.
Other tests that may be done include:
Nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or naproxen may be enough to control symptoms when only a small number of joints are involved.
Corticosteroids may be used for more severe flare-ups to help control symptoms. Because of their toxicity, long-term use of these medicines should be avoided in children.
Children who have arthritis in many joints, or who have fever, rash, and swollen glands may need other medicines. These are called disease-modifying antirheumatic drugs (DMARDs). They can help reduce swelling in the joints or body. DMARDs include:
Children with systemic JIA will likely need biologic inhibitors of IL-1 or IL-6 such as anakinra or tocilizumab.
Children with JIA need to stay active.
Exercise will help keep their muscles and joints strong and mobile.
Children who have sadness or anger about their arthritis may need extra support.
Some children with JIA may need surgery, including joint replacement.
Children with only a few affected joints may have no symptoms for a long period.
In many children, the disease will become inactive and cause very little joint damage.
The severity of the disease depends on the number of affected joints. It is less likely that symptoms will go away in these cases. These children more often have long-term (chronic) pain, disability, and problems at school. Some children may continue to have arthritis as adults.
Complications may include:
Call your provider if:
There is no known prevention for JIA.
Beukelman T, Nigrovic PA. Juvenile idiopathic arthritis: an idea whose time has gone? J Rheumatol. 2019;46(2):124-126. PMID: 30710000 www.ncbi.nlm.nih.gov/pubmed/30710000.
Nordal EB, Rygg M, Fasth A. Clinical features of juvenile idiopathic arthritis. In: Hochberg MC, Gravallese EM, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, eds. Rheumatology. 7th ed. Philadelphia, PA: Elsevier; 2019:chap 107.
Ombrello MJ, Arthur VL, Remmers EF, et al. Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications. Ann Rheum Dis. 2017;76(5):906-913. PMID: 27927641 www.ncbi.nlm.nih.gov/pubmed/27927641.
Ringold S, Weiss PF, Beukelman T, et al. 2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. Arthritis Rheum. 2013;65(10):2499-2512. PMID: 24092554 www.ncbi.nlm.nih.gov/pubmed/24092554.
Schulert GS, Minoia F, Bohnsack J, et al. Effect of biologic therapy on clinical and laboratory features of macrophage activation syndrome associated with systemic juvenile idiopathic arthritis. Arthritis Care Res (Hoboken). 2018;70(3):409-419. PMID: 28499329 www.ncbi.nlm.nih.gov/pubmed/28499329.
Ter Haar NM, van Dijkhuizen EHP, Swart JF, et al. Treatment to target using recombinant interleukin-1 receptor antagonist as first-line monotherapy in new-onset systemic juvenile idiopathic arthritis: results from a five year follow-up study. Arthritis Rheumatol. 2019;71(7):1163-1173. PMID: 30848528 www.ncbi.nlm.nih.gov/pubmed/30848528.
Wu EY, Rabinovich CE. Juvenile idiopathic arthritis. In: Kliegman RM, St. Geme JW, Schor NF, Blum NJ, Shah SS, Tasker RC, Wilson KM, eds. Nelson Textbook of Pediatrics. 21st ed. Philadelphia, PA: Elsevier; 2020:chap 180.BACK TO TOP
Review Date: 4/8/2019
Reviewed By: Gordon A. Starkebaum, MD, MACR, ABIM Board Certified in Rheumatology, Seattle, WA. Also reviewed by David Zieve, MD, MHA, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997- 2020 A.D.A.M., a business unit of Ebix, Inc. Any duplication or distribution of the information contained herein is strictly prohibited.